Chandler Robinson

CEO Chandler Robinson sold 550.2K shares of MNPR at $63.61 for $35.0M, reducing stake by 66.9%

Chandler Robinson, Chief Executive Officer, executed a substantial sale of 550,229 shares at $63.61, reducing his holdings from 822,255 shares to 272,026 shares—a reduction of 66.9% of his pre-transaction position. The $35.0M transaction represents a material liquidation of CEO equity holdings in a single transaction. This large-scale disposition by the company's top executive merits investor scrutiny regarding his commitment to the business and the confidence signaled by retaining only 272,026 shares going forward.

CEO Robinson Chandler sold 16,800 shares (16.8K) of MNPR at $40.00 for $672.0K, reducing stake by 18.6% while company reports $-2.6M net loss and zero revenue.

CEO Robinson Chandler executed a material reduction in MNPR holdings, selling 16,800 shares at $40.00 and retaining 73,472 shares post-transaction. This sale occurred against a backdrop of deteriorating fundamentals: the company reported Revenue $0.00 (latest quarter) and Net income $-2,624,972.00, with negative full-year profitability. The stock is trading -20.8% from its 52-week high of $51.89, suggesting the sale came after significant appreciation yet below peak levels. While the 30-day price movement of +20.0% and 90-day movement of +3.7% indicate recent momentum, the underlying business remains unprofitable with no current-quarter revenue, making visibility into operational recovery limited. Investors should monitor whether this 18.6% reduction in the CEO's stake reflects a broader shift in insider positioning at an unprofitable pre-commercial or early-stage biotech company.

CEO Chandler Robinson sold 33,334 shares of MNPR at $35.00 for $1,166,690.00

Chandler Robinson, Chief Executive Officer, sold 33,334 shares on 2025-04-02 at $35.00, reducing his holdings from 855,589 shares to 822,255 shares. The sale generated $1,166,690.00 and represents a -3.9% reduction in his pre-transaction position. As a CEO with substantial remaining holdings of 822,255 shares, this modest-sized open-market sale warrants standard disclosure monitoring but does not signal abnormal portfolio activity or structural changes in executive positioning.